Fintel reports that on April 17, 2025, BMO Capital upgraded their outlook for Trex (NYSE:TREX) from Market Perform to ...

Fintel reports that on April 17, 2025, BMO Capital downgraded their outlook for Beacon Roofing Supply (NasdaqGS:BECN) from ...

BMO Capital analyst John Kim maintained a Buy rating on SL Green Realty (SLG – Research Report) today and set a price target of $87.00.Stay ...

BMO Capital downgraded Novo Nordisk (NVO) to Market Perform from Outperform with a price target of $64, down from $105. The company’s obesity ...

BMO Capital on Wednesday cut its year-end 2025 S&P 500 target by 9% to 6,100 from the prior 6,700, citing the speed and severity of the recent selloff.

With the Lilly trial result and BMO report, Novo’s shares dropped by 8% on Thursday to $58.08. Conversely, Lilly's stock price jumped about 14.5% to $840. Related ...

The mounting uncertainty has now prompted BMO Capital Markets to lower its year-end target for the benchmark index. “We are revising our 2025 year-end S&P 500 price targets down to 6,100 from 6,700.

NEW YORK, April 9 (Reuters) - BMO Capital on Wednesday cut its year-end 2025 S&P 500 (.SPX), opens new tab target by 9% to 6,100 from the prior 6,700, citing the speed and severity of the recent ...

Neurogene (NASDAQ:NGNE – Get Free Report) had its target price lowered by equities researchers at BMO Capital Markets from $45.00 to $16.00 in a note issued to investors on Monday,Benzinga reports.

On Tuesday, BMO Capital Markets began coverage on Pan American Silver Corp . (NYSE:PAAS), assigning the stock a "Market Perform" rating. The research firm’s analysts cited the company’s ...

On a recent call with analysts at BMO Capital Markets, an enigmatic “former director” at the FDA’s Center for Biologics Evaluation and Research (CBER)—who resigned in March—raised ...

NEW YORK (Reuters) - BMO Capital on Wednesday cut its year-end 2025 S&P 500 target by 9% to 6,100 from the prior 6,700, citing the speed and severity of the recent selloff. In a note to clients ...